Physician profile
Eugene Pashkovetsky
NPI 1588930770
$25,912.30
in general payments reported to CMS, 2019-2025
33 companies · $3,314 in 2025
The $3,314 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,393 · 2020: $1,597 · 2021: $1,522 · 2022: $1,368 · 2023: $6,027 · 2024: $9,692 · 2025: $3,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,264 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,547 · Consulting Fee: $4,455 · Travel and Lodging: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,263.81 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,547.00 |
| Consulting Fee | $4,455.00 |
| Travel and Lodging | $767.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $13,089.95 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $2,207.56 | 2019-2025 | Mitraclip, Cardiomems, Amplatzer Amulet |
| Astrazeneca Pharmaceuticals LP | $1,933.35 | 2019-2025 | Wainua, Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $1,712.10 | 2019-2025 | |
| Pfizer INC. | $818.05 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $810.31 | 2019-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $654.22 | 2022-2025 | Onpattro, Amvuttra |
| Merck Sharp & Dohme LLC | $602.11 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Janssen Pharmaceuticals, INC | $598.58 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $355.11 | 2019-2024 | Lifevest |
| Amgen INC. | $345.10 | 2019-2024 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $338.97 | 2021-2025 | |
| Abiomed | $330.42 | 2019-2025 | Impella |
| Aop Health US, LLC | $326.40 | 2025 | Rapiblyk |
| Actelion Pharmaceuticals US, INC. | $308.43 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $214.91 | 2023-2025 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $184.71 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $172.25 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $170.01 | 2022-2023 | Arcalyst |
| Scpharmaceuticals INC. | $104.62 | 2023-2025 | |
| Bridgebio Pharma, INC. | $101.50 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $82.22 | 2021-2025 | Nexletol |
| Boston Scientific Corporation | $71.65 | 2022-2024 | Watchman Access System |
| Impulse Dynamics (USA) INC. | $63.32 | 2024 | Optimizer |
| Chiesi USA, INC. | $48.83 | 2020-2023 | Kengreal, Cleviprex |
| Regeneron Healthcare Solutions, INC. | $43.30 | 2019 | |
| Novo Nordisk INC | $42.58 | 2022-2025 | |
| Glaxosmithkline, LLC. | $38.67 | 2025 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $37.12 | 2019-2020 | |
| Amarin Pharma, INC. | $34.95 | 2020 | |
| Portola Pharmaceuticals, LLC | $25.60 | 2019 | |
| Astellas Pharma US INC | $24.68 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Pashkovetsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.